前列腺癌是男性常见的泌尿外科恶性肿瘤，居全球第二位。当与高血压同时诊断时，这种疾病尤其严重。 MKI67 是人类肿瘤细胞增殖的既定标志物，但其对前列腺癌和高血压患者的预后价值的意义需要进一步研究。在这项回顾性分析中，我们评估了 2012 年 3 月 2 日至 11 月期间的 296 名高血压前列腺癌患者2015 年 1 月 1 日。我们使用 Cox 回归模型和预测分析来评估总体生存率。此外，我们创建了列线图，并使用校准曲线验证了其准确性。在所有参与者中，有 101 人 (34.12%) 死亡。我们的多因素分析显示，MKI67 表达与死亡风险比增加（> 五倍）（风险比 5.829，95% CI 3.349-10.138，p 值 < 0.01）和进展风险比增加（两倍）（HR 2.059，95%）相关。 CI 1.368-3.102，p 值 < 0.01）。我们的Lasso分析模型显示，心力衰竭、吸烟、ACS、血清白蛋白、Gealson评分、预后营养指数、MKI67表达、手术和分期等几个因素是前列腺癌的高风险因素。为了确保每个协变量对癌症预后的贡献，我们创建了 Cox 模型列线图，它准确预测了死亡风险（C 统计量为 0.8289），并为风险评估提供了适当的校准图。MKI67 表达预测前列腺总体死亡率的不良结果癌症和高血压患者。此外，我们经过交叉验证的多变量评分（包括 MKI67）证明了预测预后的准确性。© 2024。作者获得 Federación de Sociedades Españolas de Oncología (FESEO) 的独家许可。

Prostate cancer is a common urology malignant in males, ranking second globally. The disease is especially severe when diagnosed alongside hypertension. MKI67 is an established marker of neoplastic cell proliferation in humans, but the significance of its prognostic value in patients with prostate cancer and hypertension requires further research.In this retrospective analysis, we evaluated 296 hypertensive prostate cancer patients between March 2, 2012, and November 1, 2015. We used Cox regression models and prediction analysis to assess overall survival. Furthermore, we created a nomogram and verified its accuracy using a calibration curve.Of all participants, 101 (34.12%) died. Our multi-factor analysis revealed that MKI67 expression was associated with an increased hazard ratio of death (> fivefold) (Hazard Ratio 5.829, 95% CI 3.349-10.138, p value < 0.01) and progression (twofold) (HR 2.059, 95% CI 1.368-3.102, p value < 0.01). Our Lasso analysis model displayed that several factors, including heart failure, smoking, ACS, serum albumin, Gealson score, prognostic nutritional index, MKI67 expression, surgery, and stage were high risks of prostate cancer. To ensure each covariate's contribution to cancer prognosis, we created a Cox model nomogram, which accurately predicted the risk of death (C-statistic of 0.8289) and had a proper calibration plot for risk assessment.MKI67 expression predicts poor outcomes for overall mortality in prostate cancer and hypertension patients. Additionally, our cross-validated multivariate score, which includes MKI67, demonstrated accuracy efficacy of predicting prognosis.© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).